Calyxt Reports 1st Quarter Financial Results

Calyno High Oleic Soybean Oil is the first ever gene-edited food
product to successfully undergo review by the USDA and FDA and be
commercialized in the U.S.

Calyno High Oleic Soybean Oil is now available from one of the
world’s largest broadline foodservice distributors

Sold out of seed and 3x acre growth, with 55,000 Calyxt soybean
acres contracted for the 2019 growing season

Cash and cash equivalents of $85.7M at March 31, 2019

2019 seed deliveries began in second quarter, cash receipts of
$1.8M expected over next 90 days

(NASDAQ: CLXT), a healthy food ingredient company, today
announced its results for the first quarter ended March 31, 2019.

Investor Call Details

Calyxt will host an investor call on May 8, 2019 at 8:30 a.m. Eastern
Time – 7:30 a.m. Central Time to discuss its financial results and
provide a general business update.

US & Canada only: +1 (877) 407-9747
International: +1 (412)

In addition, a replay of the call will be available for one month
following the conference by calling +1 (877) 660-6853 (Toll Free US &
Canada); +1 (201) 612-7415 (Toll Free International).

The archived webcast of this event may be accessed through the Calyxt
website, using passcode 13673206.

“In the first quarter of 2019, we achieved a monumental milestone for
Calyxt with the successful commercial launch of Calyno oil. We are
thrilled to see our High Oleic Soybean Oil either met or exceeded the
performance and quality standards of the commercially available oils for
qualities including fry life, trans-fat content, saturated fat content
and flavor transfer. Following the initial commercial sale, we have
identified and vetted a series of food customer opportunities and we are
excited to announce that as of late April Calyno oil is available from
one of the world’s largest broadline foodservice distributors” said Jim
Blome, CEO of Calyxt. “On the farmer side, we are sold out of seed for
the 2019 growing season and have tripled our acres from 2018 – we have
partnered with over 150 selected growers who have contracted over 55,000
Calyxt soybean acres.”


As previously announced, Calyxt completed a consultation with the Food
and Drug Administration (FDA) for its High Oleic Soybean. After review,
FDA had no further questions concerning human food ingredients or animal
food derived from our High Oleic Soybean. Calyno oil is the first
gene-edited food product to undergo such review and be commercialized in
the U.S.

High Oleic Soybean

  • Completed the first sales of Calyxt High Oleic Soybean Oil, Calyno,
    in the foodservice channel. We are focused on selling this oil for
    frying applications based on its extended fry life, flavor
    performance, and heart-healthy qualities. Within the foodservice
    channel we are focused on certain categories of commercial restaurants
    and usage in other foodservice segments including Business & Industry,
    Healthcare and Education.
  • As of late April, Calyno oil is available from one of the world’s
    largest broadline foodservice distributors
    providing a growth
    opportunity for the distribution and integration of our soybean oil in
    the foodservice business nationwide. We are vetting further
    engagements with food companies to focus on high volume sales based on
    our growing acreage.
  • Completed the first sales of High Oleic Soybean Meal as a
    premium feed ingredient for livestock.
  • Cooperation with Agtegra continues to scale as we leverage
    their resources to contract acreage, for agronomic support, grain
    storage, and for rail shipping.
  • 2019 acreage contracting complete. We are sold out of seed for
    the 2019 growing season and have contracted over 55,000 acres, more
    than triple our 2018 acreage. These contracts are with more than 150
    growers. Our grower retention rate is over 73 percent.

Product Candidate Pipeline

  • Development of High Fiber Wheat product candidate. Preliminary
    results showed our High Fiber Wheat product candidate produced white
    flour with at least three times more dietary fiber than standard white
    wheat flour. This product candidate is currently in Phase II of our
    development process and on track for commercialization as early as
    2022. Our High Fiber Wheat product has been determined to be
    non-regulated by the U.S. Department of Agriculture (USDA).
  • Additional varieties of our High Oleic Soybean are in Phase III of
    our development process.
    We expect these varieties will expand our
    growing zones and will be commercialized in 2020 and 2021.

Financial Highlights

Cash, cash equivalents and restricted cash were $85.7 million at March
31, 2019. We intend to continue to manage the use of cash and expect to
have sufficient cash to fund the business into early 2021.

Our cash spend for 2019 is estimated at between $3 million and $3.5
million per month based on the increase in acreage contracted for the
2019 season and will be focused in these areas:

  • Supporting our product pipeline, including development of additional
    varieties and traits for soybeans, high fiber wheat and alfalfa, as
    well as continuing to build our strong intellectual property portfolio;
  • Continuing to drive the commercialization of our High Oleic Soybean
    products including our Calyno oil and High Oleic Soybean meal, which
    includes spending for sales and marketing support, product samples,
    and costs associated with agricultural activities including seed
    production, grain purchases, and processing and distribution; and
  • Strengthening our organization, including hiring talented personnel,
    developing our IT systems, maintaining public company reporting and
    compliance and refining internal controls.

For the three months ended March 31, 2019, we incurred losses from
operations of $7.4 million and used net cash in operating activities of
$9.3 million.

For the three months ended March 31, 2018, we incurred losses from
operations of $4.4 million and used net cash in operating activities of
$6.6 million.

About Calyxt

Calyxt is committed to making the food you love a healthier choice. The
care we take extends beyond nutritional value. We partner with farmers
and food companies to deliver traceable plant-based products developed
to be healthier and more sustainable than their conventional
counterparts. We use cutting edge plant breeding techniques to develop
products that help improve diets by reducing bad fats, allergens and
toxins. Today oil from our high oleic soybean plants has lower saturated
fats than commodity soybean oil. We are also developing high fiber wheat
designed to provide an excellent source of daily fiber when incorporated
into wheat-based foods. We continuously pursue innovation to deliver
good food that is good for you.

Calyxt is located in Roseville, MN, and is listed on the Nasdaq market
(ticker: CLXT). For further information please visit our website at

Calyxt™, Calyno™ and the corporate logo are trademarks owned by Calyxt,

Calyxt Forward-Looking Statements

This communication contains “forward-looking statements” within the
meaning of the safe harbor provisions of the U.S. Private Securities
Litigation Reform Act of 1995. In some cases, you can identify these
statements by forward-looking words such as “may,” “might,” “will,”
“should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,”
“predicts,” “potential” or “continue,” the negative of these terms and
other comparable terminology. These forward-looking statements, which
are subject to risks, uncertainties and assumptions about us, may
include projections of our future financial performance, our anticipated
growth strategies and anticipated trends in our business. These
statements are only predictions based on our current expectations and
projections about future events. There are important factors that could
cause our actual results, level of activity, performance or achievements
to differ materially from the results, level of activity, performance or
achievements expressed or implied by the forward-looking statements,
including those factors discussed under the caption entitled “Risk
Factors” in our Annual Report on Form 10-K, along with our other filings
with the U.S. Securities and Exchange Commission. We do not assume any
obligation to publicly provide revisions or updates to any
forward-looking statements, whether as a result of new information,
future developments or otherwise, should circumstances change, except as
otherwise required by applicable laws.



(In Thousands, Except Par Value and Share Amounts)

    March 31,



  December 31,


Current assets:
Cash and cash equivalents





Restricted cash 381 381
Trade accounts receivable 124

Due from related parties 130 46
Inventory 379

Prepaid expenses and other current assets     1,778     1,301
Total current assets 87,023 95,522
Non-current restricted cash 1,120 1,113
Land, buildings, and equipment 21,854 21,850
Other non-current assets     674     306
Total assets   $ 110,671   $ 118,791

Liabilities and stockholders’ equity

Current liabilities:
Accounts payable $ 724 $ 818
Accrued expenses 1,610 2,007
Accrued compensation and benefits 887 1,305
Due to related parties 875 1,905
Current portion of financing lease obligations 264 258
Other current liabilities     290     711
Total current liabilities 4,650 7,004
Financing lease obligations 18,162 18,227
Other non-current liabilities     156     163
Total liabilities     22,968     25,394
Stockholders’ equity:

Common stock, $0.0001 par value; 275,000,000 shares authorized;
shares issued and 32,692,189 shares outstanding as of
31, 2019 and 32,664,429 shares issued and 32,648,893 shares
as of December 31, 2018

3 3
Additional paid-in capital 177,750 176,069
Common stock in treasury, at cost; 15,536 shares (230) (230)
Accumulated deficit     (89,820)     (82,445)
Total stockholders’ equity     87,703     93,397
Total liabilities and stockholders’ equity   $ 110,671   $ 118,791



(Unaudited and in Thousands Except Shares and Per Share Amounts)

Three months ended March 31,
      2019   2018



$ 11
Operating expenses:
Cost of revenue 34
Research and development 2,044 1,048
Selling, general and administrative 5,241 2,676
Management Fees     361   583
Total operating expenses     7,680   4,307
Loss from operations (7,523) (4,296)
Interest, net 172 (68)
Foreign currency transaction (loss) gain     (24)   (6)
Loss before income taxes (7,375) (4,370)
Income taxes      
Net loss   $ (7,375) $ (4,370)
Basic and diluted loss per share   $ (0.23) $ (0.16)
Weighted average shares outstanding – basic and diluted     32,677,944   27,851,162



(Unaudited and in Thousands)

Three months ended March 31,
      2019   2018
Operating activities

Net loss





Adjustments to reconcile net loss to net cash used in operating

Depreciation 342 156
Stock-based compensation 1,556 40
Unrealized foreign exchange gain 8
Changes in operating assets and liabilities:
Trade accounts receivable (124)
Due to/from related parties (1,114) (496)
Inventory (379)
Prepaid expenses and other assets (624) (880)
Accounts payable (94) (310)
Accrued expenses (397) 182
Accrued compensation and benefits (418) (456)
Other accrued liabilities     (708)   (439)
Net cash used by operating activities     (9,335)   (6,565)
Investing activities
Purchases of land, buildings and equipment     (346)   (41)
Net cash used by investing activities     (346)   (41)
Financing activities
Deferred offering costs (69)
Proceeds from the exercise of stock options     125   714
Net cash provided by financing activities     125   645
Net decrease in cash, cash equivalents and restricted cash (9,556) (5,961)
Cash, cash equivalents and restricted cash – beginning of period     95,288   56,664
Cash, cash equivalents and restricted cash – end of period   $ 85,732 $ 50,703


Jennifer Moore, VP Communications
Phone: +1
(917) 580-1088


Simon Harnest, VP Corporate Strategy and Finance
+1 (646) 385-9008

error: Content is protected !!